First MAb approved for treatment of metastatic breast cancer.

T. L. Brenner; V. R. Adams

doi:10.1016/s1086-5802(16)30498-3

First MAb approved for treatment of metastatic breast cancer.

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Original language	English
Pages (from-to)	236-238
Number of pages	3
Journal	Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Volume	39
Issue number	2
DOIs	https://doi.org/10.1016/s1086-5802(16)30498-3
State	Published - 1999

Bibliographical note

Funding Information:
is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Funding

is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Funders	Funder number
Ameri can Pharmaceutical Asso ciation

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1086-5802(16)30498-3

Cite this

@article{af98ab73861f43cc828a1008073bd25f,

title = "First MAb approved for treatment of metastatic breast cancer.",

author = "Brenner, \{T. L.\} and Adams, \{V. R.\}",

note = "Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.",

year = "1999",

doi = "10.1016/s1086-5802(16)30498-3",

language = "English",

volume = "39",

pages = "236--238",

number = "2",

}

TY - JOUR

T1 - First MAb approved for treatment of metastatic breast cancer.

AU - Brenner, T. L.

AU - Adams, V. R.

N1 - Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

PY - 1999

Y1 - 1999

UR - http://www.scopus.com/inward/record.url?scp=0033093978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033093978&partnerID=8YFLogxK

U2 - 10.1016/s1086-5802(16)30498-3

DO - 10.1016/s1086-5802(16)30498-3

M3 - Review article

C2 - 10079656

AN - SCOPUS:0033093978

SN - 1086-5802

VL - 39

SP - 236

EP - 238

JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

IS - 2

ER -

First MAb approved for treatment of metastatic breast cancer.

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this